Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Hepatol. Aug 27, 2013; 5(8): 439-444
Published online Aug 27, 2013. doi: 10.4254/wjh.v5.i8.439
Published online Aug 27, 2013. doi: 10.4254/wjh.v5.i8.439
Noninvasive assessment of liver damage in chronic hepatitis B
Mehmet Celikbilek, Department of Gastroenterology, Medical School, Bozok University, 66200 Yozgat, Turkey
Serkan Dogan, Sebnem Gursoy, Alper Yurci, Omer Ozbakır, Kadri Guven, Mehmet Yucesoy, Department of Gastroenterology, Medical School, Erciyes University, 38039 Kayseri, Turkey
Gokmen Zararsız, Department of Biostatistics and Medical Informatics, Medical School, Erciyes University, 38039 Kayseri, Turkey
Author contributions: Celikbilek M, Dogan S, Gursoy S, Yurci A, Ozbakır O, Guven K and Yucesoy M contributed to design of the study; Celikbilek M, Dogan S and Gursoy S contributed to data collection; Celikbilek M and Dogan S drafted the manuscript, and revised it in accordance with suggestions from the other authors; Gursoy S contributed to the study conception, analysis data, participated in the critical revision of the manuscript for important intellectual content; Zararsız G performed the statistical analysis; Gursoy S, Yurci A, Ozbakır O, Guven K and Yucesoy M contributed to interpretation of data; Yurci A, Ozbakır O, Guven K and Yucesoy M participated in the critical revision of the manuscript for important intellectual content.
Correspondence to: Mehmet Celikbilek, MD, Department of Gastroenterology, Medical School, Bozok University, 66200 Yozgat, Turkey. drcelikbilek@yahoo.com
Telephone: +90-505-6615375 Fax: +90-354-2140612
Received: April 14, 2013
Revised: June 10, 2013
Accepted: July 18, 2013
Published online: August 27, 2013
Processing time: 159 Days and 17.3 Hours
Revised: June 10, 2013
Accepted: July 18, 2013
Published online: August 27, 2013
Processing time: 159 Days and 17.3 Hours
Core Tip
Core tip: Due to the limitations of liver biopsy, the use of non-invasive markers has emerged in recent years. The aspartate aminotransferase/platelet ratio index (APRI) is used to determine chronic hepatitis C patients with advanced fibrosis. Neutrophil-lymphocyte (N/L) ratio is higher in patients with advanced fibrosis and considered as a novel non-invasive marker to predict advanced disease in non-alcoholic steatohepatitis. This study showed that N/L ratio is negatively correlated with HAI in chronic hepatitis B (CHB). APRI score may be useful to exclude cirrhosis in CHB patients.